1st Quarter - Amendment

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$260,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 14, 2017 $260,000 Replaced
1st Quarter - Amendment (this page) Jul 27, 2017 $260,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Agriculture, Rural Development, Food and Drug Administration, and related Agencies Appropriations seeking Food and Drug Administration funding. Discussion with the House on opioid addiction.

LobbyistCovered position, as disclosed
NICHOLAS GENTILE —
JOSEPH M HILL —
JILLANNE SCHULTE —
CHRISTOPHER J TOPOLESKI —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Labor, Dept of (DOL); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, MIPS/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing.

LobbyistCovered position, as disclosed
NICHOLAS GENTILE —
JOSEPH M HILL —
JILLANNE SCHULTE —
CHRISTOPHER J TOPOLESKI —

Contacted: HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 592 (115th), S. 109 (115th)

Pharmacy PHA

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage

LobbyistCovered position, as disclosed
NICHOLAS GENTILE —
JOSEPH M HILL —
JILLANNE SCHULTE —
CHRISTOPHER J TOPOLESKI —

Contacted: HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL); Health & Human Services, Dept of (HHS); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.